Metastatic Melanoma
Showing NaN - NaN of 30
Metastatic Melanoma, Skin Cancer Trial in Boston (Ipilimumab, Nivolumab, Cryoablation)
Not yet recruiting
- Metastatic Melanoma
- Skin Cancer
- Ipilimumab
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Mar 9, 2023
Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in
Active, not recruiting
- Metastatic Melanoma
- +22 more
- Ipilimumab
- +3 more
-
Birmingham, Alabama
- +24 more
Jan 19, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +20 more
- Ipilimumab
- +3 more
-
Tampa, Florida
- +6 more
Jan 13, 2023
Melanoma, Metastatic Melanoma Trial in Boston (CDX-301, NEOVAX, Nivolumab)
Recruiting
- Melanoma
- Metastatic Melanoma
- CDX-301
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 12, 2023
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma Trial in United
Recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- +12 more
- Memantine
- +4 more
-
Tucson, Arizona
- +60 more
Jan 11, 2023
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor Trial in Canada,
Active, not recruiting
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- +20 more
- Pembrolizumab
- Ziv-Aflibercept
-
Tampa, Florida
- +8 more
Jan 3, 2023
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Tumor Trial in
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Dabrafenib
- +4 more
-
Phoenix, Arizona
- +48 more
Jan 3, 2023
Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, NSCLC Trial in Worldwide (Lifileucel, LN-145, Pembrolizumab)
Recruiting
- Metastatic Melanoma
- +2 more
- Lifileucel
- +5 more
-
La Jolla, California
- +44 more
Dec 16, 2022
Unresectable Melanoma, Metastatic Melanoma, Stage III Melanoma Trial in Boston (Sargramostim (GM-CSF), Pembrolizumab
Recruiting
- Unresectable Melanoma
- +3 more
- Sargramostim (GM-CSF)
- Pembrolizumab (anti-PD-1)
-
Boston, Massachusetts
- +1 more
Jul 6, 2022
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,
Active, not recruiting
- BRAF V600E Mutation Present
- +9 more
- Dabrafenib
- +4 more
-
Boston, Massachusetts
- +1 more
Jun 28, 2022
Metastatic Melanoma Trial in United States (Placebo for antibiotic, Vancomycin pretreatment, Nivolumab)
Completed
- Metastatic Melanoma
- Placebo for antibiotic
- +4 more
-
Los Angeles, California
- +6 more
Jun 7, 2022
Metastatic Melanoma Trial in Boston (Pembrolizumab, Infliximab, Placebo)
Recruiting
- Metastatic Melanoma
- Pembrolizumab
- +2 more
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Apr 6, 2022
Metastatic Melanoma Trial in Boston (Tremelimumab, MEDI3617)
Active, not recruiting
- Metastatic Melanoma
-
Boston, Massachusetts
- +1 more
Mar 22, 2022
Unresectable Melanoma, Metastatic Melanoma Trial in France, United States (Nivolumab, Ipilimumab, Placebo)
Completed
- Unresectable Melanoma
- Metastatic Melanoma
- Nivolumab
- +2 more
-
San Francisco, California
- +20 more
Feb 16, 2022
Metastatic Melanoma Trial in United States (ipilimumab, nivolumab)
Active, not recruiting
- Metastatic Melanoma
-
Hartford, Connecticut
- +11 more
Mar 10, 2022
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)
Terminated
- BRAF V600E Mutation Present
- +7 more
- Dabrafenib
- +4 more
-
Boston, Massachusetts
- +1 more
Mar 9, 2022
Metastatic Castration-resistant Prostrate Cancer, Renal Cell Carcinoma, Metastatic Melanoma Trial in United States (BMS-936558
Completed
- Metastatic Castration-resistant Prostrate Cancer
- +3 more
- BMS-936558 (MDX-1106)
-
Scottsdale, Arizona
- +12 more
Dec 1, 2021
Melanoma, Metastatic Melanoma Trial in Boston (Ipilimumab, Nivolumab, Troriluzole)
Recruiting
- Melanoma
- Metastatic Melanoma
- Ipilimumab
- +3 more
-
Boston, Massachusetts
- +1 more
Sep 17, 2021
Advanced Cancer, Metastatic Melanoma, Metastatic NSCLC Trial in Worldwide (LY3214996, Midazolam, Abemaciclib)
Active, not recruiting
- Advanced Cancer
- +3 more
- LY3214996
- +6 more
-
Washington, District of Columbia
- +12 more
Sep 2, 2021
Metastatic Melanoma Trial in United States (NEO-PV-01, Nivolumab, Adjuvant)
Terminated
- Metastatic Melanoma
- NEO-PV-01
- +4 more
-
Scottsdale, Arizona
- +7 more
Sep 1, 2020
Cancer, Malignancy, Neoplasia Trial in United States (ASN007: ascending doses, ASN007 RD)
Completed
- Cancer
- +18 more
- ASN007: ascending doses
- ASN007 RD
-
Tampa, Florida
- +4 more
Jul 7, 2020
Advanced Melanoma, Metastatic Melanoma Trial in Netherlands, Spain, United States (Nivolumab, Ipilimumab)
Completed
- Advanced Melanoma
- Metastatic Melanoma
- Nivolumab
- Ipilimumab
-
Los Angeles, California
- +13 more
Nov 14, 2019